Top

Published in:

01-02-2012 | SHORT REPORT

Anti-leukemic activity of Dasatinib in both p53^wild-type and p53^mutated B malignant cells

Authors: Raffaella Bosco, Marco Rabusin, Rebecca Voltan, Claudio Celeghini, Federica Corallini, Silvano Capitani, Paola Secchiero

Published in: Investigational New Drugs | Issue 1/2012

Summary

The multi-kinase inhibitor Dasatinib induced a variable but significant decrease of viability in both p53^wild-type (EHEB, JVM-2, JVM-3) and p53^mutated (MEC-1, MEC-2, BJAB) prolymphocytic B leukemic cells, due to a combination of cell cycle block in G1 and apoptosis. Antibody phospho-kinase array analysis revealed that Dasatinib inhibited the phosphorylation of various kinases, including ERK1/2 and p38/MAPK as well as of STAT3 transcription factors, in both p53^wild-type and p53^mutated cells. Therefore, Dasatinib might offer a novel therapeutic strategy not only for p53^wild-type, but also for p53^mutated B malignancies that have the worst prognosis and urgently need innovative therapeutic approaches.

Available only for authorised users

Talpaz M, Shah NP, Kantarjian H et al (2006) Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. New Engl J Med 354:2531–2541PubMedCrossRef

Amrein L, Hernandez TA, Ferrario C et al (2008) Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabine in vitro. Br J Haematol 143:698–706PubMedCrossRef

Veldurthy A, Patz M, Hagist S et al (2008) The kinase inhibitor dasatinib induces apoptosis in chronic lymphocytic leukemia cells in vitro with preference for a subgroup of patients with unmutated IgVH genes. Blood 112:1443–1452PubMedCrossRef

Secchiero P, Zerbinati C, di Iasio MG et al (2007) Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8:395–403PubMedCrossRef

Secchiero P, Zerbinati C, Melloni E et al (2007) The MDM-2 antagonist Nutlin-3 promotes maturation of acute myeloid leukemic blasts. Neoplasia 9:853–861PubMedCrossRef

Tavolaro S, Chiaretti S, Messina M et al (2010) Gene expression profile of protein kinases reveals a distinctive signature in chronic lymphocytic leukemia and in vitro experiments support a role of second generation protein kinase inhibitors. Leuk Res 34:733–741PubMedCrossRef

Zenz T, Kröber A, Sherer K et al (2008) Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up. Blood 112:3322–3329PubMedCrossRef

Zauli G, Re MC, Furlini G, Giovannini M, La Placa M (1992) Human immunodeficiency virus type 1 envelope glycoprotein gp120-mediated killing of human haematopoietic progenitors (CD34⁺ cells). J Gen Virol 73:417–421PubMedCrossRef

Secchiero P, Zerbinati C, Rimondi E et al (2004) TRAIL promotes the survival, migration and proliferation of vascular smooth muscle cells. Cell Mol Life Sci 61:1965–1974PubMedCrossRef

10.

Milani D, Zauli G, Rimondi E et al (2003) Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells. J Neurochem 86:126–135PubMedCrossRef

11.

Milani D, Mazzoni M, Borgatti P, Zauli G, Cantley L, Capitani S (1996) Extracellular human immunodeficiency virus type-1 Tat protein activates phosphatidylinositol 3-kinase in PC12 neuronal cells. J Biol Chem 271:22961–22964PubMedCrossRef

12.

Demetri GD, Lo Russo P, MacPherson IRJ (2009) Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin Cancer Res 15:6232–6240PubMedCrossRef

13.

Sainz-Perez A, Gary-Gouy H, Gaudin F et al (2008) IL-24 induces apoptosis of chronic lymphocytic leukemia B cells engaged into the cell cycle through dephosphorylation of STAT3 and stabilization of p53 expression. J Immunol 181:6051–6060PubMed

14.

Ghosh AK, Kay NE, Secreto CR, Shanafelt TD (2009) Curcumin inhibits prosurvival pathways in chronic lymphocytic leukemia B cells and may overcome their stromal protection in combination with EGCG. Clin Cancer Res 15:1250–1258PubMedCrossRef

15.

Mirandola P, Ponti C, Gobbi G et al (2004) Activated human NK and CD8+ T cells express both TNF-related apoptosis inducing ligand (TRAIL) and TRAIL receptors, but are resistant to TRAIL-mediated cytotoxicity. Blood 104:2418–2424PubMedCrossRef

16.

Cheng JC, Kinjo K, Judelson DR et al (2008) CREB is a critical regulator of normal hematopoiesis and leukemogenesis. Blood 111:1182–1192PubMedCrossRef

Title: Anti-leukemic activity of Dasatinib in both p53wild-type and p53mutated B malignant cells
Authors: Raffaella Bosco
Marco Rabusin
Rebecca Voltan
Claudio Celeghini
Federica Corallini
Silvano Capitani
Paola Secchiero
Publication date: 01-02-2012
Publisher: Springer US
Published in: Investigational New Drugs / Issue 1/2012
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI: https://doi.org/10.1007/s10637-010-9564-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Summary

Please log in to get access to this content

Other articles of this Issue 1/2012

Expression of Nur77 induced by an n-butylidenephthalide derivative promotes apoptosis and inhibits cell growth in oral squamous cell carcinoma

Dose modification of alemtuzumab in combination with dexamethasone, cytarabine, and cisplatin in patients with relapsed or refractory peripheral T-cell lymphoma: analysis of efficacy and toxicity

Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab

Synthesis and antitumor activity of novel aroylthiourea derivatives of podophyllotoxin

An international, multicenter phase II trial of bortezomib in patients with hepatocellular carcinoma

17α-Alkynyl 3α, 17β-androstanediol non-clinical and clinical pharmacology, pharmacokinetics and metabolism

Keynote webinar | Spotlight on antibody–drug conjugates in cancer